A Phase II Randomized Study of HIV-Specific T-Cell Gene Therapy in Subjects with Undetectable Plasma Viremia on Combination Antiretroviral Therapy
Open Access
- 1 June 2002
- journal article
- clinical trial
- Published by Elsevier BV in Molecular Therapy
- Vol. 5 (6), 788-797
- https://doi.org/10.1006/mthe.2002.0611
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptorNature Biotechnology, 2002
- Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral TherapyNew England Journal of Medicine, 1999
- Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug TherapyNew England Journal of Medicine, 1998
- Cytotoxic-T-Cell Responses, Viral Load, and Disease Progression in Early Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Critical role for β7 integrins in formation of the gut-associated lymphoid tissueNature, 1996
- Antiviral Effect and Ex Vivo CD4 + T Cell Proliferation in HIV-Positive Patients as a Result of CD28 CostimulationScience, 1996
- Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8 + T CellsScience, 1995
- Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the DonorNew England Journal of Medicine, 1995
- Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.The Journal of Experimental Medicine, 1993